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Abstract
Background: Asthma is an increasing problem in this country and others. Although medications
for the treatment of asthma abound and are improving, there are inherent risks and side effects
with all of them. Intravenous magnesium has been employed in the treatment of acute asthma, but
its use has not become universal, nor has it been studied for the treatment of chronic asthma. It is
known to be a safe drug with minimal side effects. In this study, the author investigates the use of
magnesium and other nutrients in the treatment of both acute and chronic asthma.
Methods:  In this non-blinded outcome study, following informed consent, forty-three (43)
randomly selected volunteer patients with both acute and chronic asthma were treated with IV
infusions described herein. All patients were observed with spirometry 10 minutes post-infusion;
two sub-groups of patients were also observed after multiple infusions over a short period of time
(less than one month) and a longer period of time (average 5.8 months). Pulmonary function was
analyzed by spirometric testing with pre- and post-infusion spirometric measurements with the
pre/post group. For longer term (Trend) patients, baseline spirometry measurements were
compared to spirometry measurements after patients had received multiple infusions over a period
of time. Eight (8) patients were measured for both pre/post and Trend data.
Results: The 38 pre-infusion/post-infusion patients with acute and chronic asthma demonstrated
an overall average improvement (percentage improvement in percent predicted) of 45%. The 13
patients measured for improvement over time (Trend data, average duration 5.82 months),
demonstrated an overall average improvement (percentage improvement in percent predicted) of
57%. Of the 13 patients in the multiple infusion group, 9 patients who received longer-term therapy
(average duration of 12.58 months) for chronic asthma demonstrated an overall average
improvement of 95% (percentage improvement in percent predicted).
Conclusion: The use of intravenous treatment with multiple nutrients, including magnesium, for
acute and chronic asthma may be of considerable benefit. Pulmonary function improved
progressively the longer patients received treatment.
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Background
Asthma has been a major focus for physicians in recent
years because both the incidence and the mortality appear
to be increasing, especially within certain ethnic or geopo-
litical groups [1-3]. This increase has been blamed vari-
ously on different types of inhalers used for asthma, [4]
chemical environmental pollution, mostly of the air, [5]
increased reporting incidences and many other factors.
No matter what the cause, the incidence of asthma has
appeared to increase and to worsen over the years, even if
it may appear to be more stable recently [6,7].
In addition, asthma has become increasingly more diffi-
cult to treat. Several studies indicate the mortality of
asthma is higher and that the incidence of status asthmat-
icus patients seen in emergency rooms has increased [8].
Despite many newer drugs for asthma, people are dying
more frequently from this illness.
In view of these rather grim realizations and statistics, the
author has undertaken research of a modality in an
attempt to mitigate the effects of asthma. A most promis-
ing treatment appears to be intravenous therapy with
magnesium and other nutrients, both for the acute and
chronic illness.
The use of IV parenteral nutrient therapy for asthma was
begun in the author's office in the late 1980's, soon after
the first papers appeared in the literature involving the use
of IV magnesium for the treatment of acute asthma [9].
Many papers have followed since then, but they have con-
centrated primarily on intravenous magnesium, usually in
the sulfated form [10-35]. Most of these authors have
found that magnesium sulfate, via IV infusion, is benefi-
cial for the treatment of asthma, and often extremely so.
However, not all study results have been positive. This
may have been due to the way the infusions were admin-
istered, the dose employed, or other factors such as sever-
ity of disease.
The author's IV protocols were expanded based on studies
of the theoretical and known effects of various other nutri-
ents on both acute and chronic asthma, as a result of pre-
vious work with general parenteral nutrients. Dr.
Jonathan Wright's work with molybdenum [36] for the
treatment of chronic asthma, as well as his and others'
work with vitamin B-12, [37,38] further influenced this
study. Based on the early studies with magnesium and the
work with molybdenum and B-12, the author undertook
to employ other added nutrients to test the combined
clinical efficacy.
Methods
This study began with a total of 49 patients who came to
the author's clinic for treatment from 1989 through 1998.
These patients all had moderate to severe (steroid-
dependent) asthma, and all required one or more medica-
tions for asthma. Patients were asked to volunteer for the
study, and all signed appropriate informed consent docu-
ments. Not all patients treated in the clinic volunteered
for the study, and no patient who volunteered was
excluded unless therapy appeared to fail.
During the study, 6 patients showed no initial response to
the first treatment. These 6 patients were considered non-
responders and were not included in the data pool in this
study, since there was no measurable improvement with a
trial infusion. Forty-three (43) patients of mixed Cauca-
sian descent were eventually enrolled, consisting of 16
males and 27 females, with a combined average age of 53
years.
Patients evaluated for pre- and post infusion results were
given the IV "Push" protocol indicated in Table 1. These
patients were evaluated at random times at the clinic;
some were in mild to moderate distress. This IV was
administered by a nurse with a 35 cc BD syringe and a 23–
25-gauge butterfly needle attached, with the amount of
sterile water indicated. The IV Push infusions were admin-
istered over 10–15 minutes, rapidly enough to cause the
patient to experience some sensation of warmth and
flushing, but not rapidly enough to cause significant
hypotension. Patients in the longer-term group ("Trend")
were given one Push protocol initially. Subsequent to this,
the "Infusion" protocol was given as an IV infusion in 250
cc of Sterile Water, generally over 45–60 minutes. Sterile
Water was used to keep osmolarity in tolerable ranges. Of
the thirteen (13) patients in trend group, eight were also
evaluated in the pre/post group, while five (5) were eval-
uated only for Trend data. In the Trend group, the pre/
post data was taken from the initial IV session.
Thirteen (13) patients were given the Infusion (Table 1)
protocol and evaluated for variable lengths of time with
serial spirometry testing for Trend data. Spirometry trend
data was obtained using a baseline pulmonary function
test and comparing data obtained from that test with the
results of the spirometry results at the end of the treatment
period.
All patients were evaluated pre- and post-IV treatment
with spirometry (pulmonary function testing, or PFT),
using the SX-Platinum® computerized pulmonary func-
tion testing program. Spirometry was done immediately
(within 10 minutes) after the protocols were adminis-
tered. The computerized results were based on predicted
Knudson normal for age, sex, weight and height.
The Trend group was further divided into "Short Term"
and "Long Term" groups. The Short Term group consistedNutrition Journal 2004, 3 http://www.nutritionj.com/content/3/1/6
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of those patients who had "trend" data measured for one
month or less, while those in the Long Term group were
treated for up to 19 months. There were 4 patients in the
Short Term group, 3 females and 1 male, average age 62,
with an average duration of therapy of 0.43 mos. and 3.25
infusions per patient. There were 9 patients in the Long
Term group, 6 females and 3 males, average age 53, with
an average duration of therapy 12.58 mos. and 9.25 infu-
sions per patient.
The average length of treatment periods for combined
Trend patients was 5.82 months, with the shortest being
0.2 months. IV's were given anywhere from twice weekly
to once every few months, with an average of 6.77 IV's per
patient, or 1.16 IV's per patient per month.
Parameters monitored in all patients were Total Forced
Vital Capacity (FVC), Forced Expiratory Flow in 1 second
(FVC 1.0), Peak Expiratory Flow (PEF), Forced Expiratory
Flow through 25% to 75% of exhalation (FEF 25–75%)
and Forced Expiratory Flow through 75% to 85% of exha-
lation (FEF 75–85%).
Preservative-free nutrients were used without exception,
and there were no serious systemic and no local reactions
at any time during therapy. Early in the study some
patients experienced lightheadedness, nausea or near
fainting with rapid IV infusions. This was secondary to
magnesium-induced hypotension, and this problem was
recognized early in the study and avoided.
Results
Results were measured as percentage improvement of the
percentage predicted on the Knudsen scale. For example,
if the result of a parameter of the pre-infusion pulmonary
function test was calculated as 50% of predicted normal,
and IV treatment resulted in a value of 75% of predicted
normal for that same parameter, the percentage improve-
ment for that particular parameter would be entered as
50%.
The 38 pre-infusion/post-infusion patients demonstrated
an average improvement of 28% in FVC, 44% in FEV 1,
44% in PEF, 54% in FEF 25–75 and 38% in FEF 75–85,
with an overall average improvement of 45% (Tables 2,3).
The 13 patients measured for improvement over time
(sequential data, average duration 5.82 months with an
average of 1.66 infusions/patient/mo.) for chronic
asthma showed an average improvement of 50% in FVC,
57% in FEV 1, 64% in PEF, 64% in FEF 25–75 and 44% in
FEF 75–85, with an overall average improvement of 57%
(Tables 4,5).
Of the 13 patient multiple infusion group, 4 patients who
received Short Term therapy (infusions for an average
duration of a month or less) for chronic asthma demon-
strated an average improvement of 40% in FVC, 43% in
FEV 1, 45% in PEF, 36% in FEF 25–75 and 6% in FEF 75–
85, with an overall average improvement of 34% (Table
6). Nine (9) patients who received Long Term therapy
(infusions for an average duration of 12.58 months) for
chronic asthma demonstrated an average improvement of
59% in FVC, 87% in FEV 1, 88% in PEF, 128% in FEF 25–
75 and 113% in FEF 75–85, with an overall average
improvement of 95% (Table 7).
Discussion
Although there were no age-matched control patients in
this outcome study, and certainly uncontrolled variables,
considerable improvement was observed after parenteral
infusion therapy with multiple nutrients, both for pre/
post treatment and treatment over time. There was more
pronounced improvement after longer-term treatment.
Patients who received treatment for longer than a month
Table 1: Intravenous Protocols Used for Acute and Chronic Asthma
Nutrient mOsm/ml "Push" Protocol (ml) Infusion Protocol (ml)
Ascorbic acid 500 mg./ml 5.8 3 12
B-12 (hydroxycobalamine) 1000 mcg./ml .30 1 1
B-6 (pyridoxine) 100 mg./ml 1.11 2 5
B-complex 100 mg./ml 2.14 2 2
Calcium gluconate 10% (100 mg./ml) .72 2 2
Magnesium sulfate 500 mg./ml 4.06 4–5 5–6
Mineral mix ** .57 1
Molybdenum 500 mcg./ml .10 1
Pantothenic acid ("B-5") 250 mg./ml .85 2 2
Sterile Water 0 13–14 250
** Mineral mix formulation: Copper 1 mg./ml, chromium 50 mcg./ml, manganese 100 mcg./ml, molybdenum 250 mg./ml, selenium 200 mcg./ml, 
vanadium 100 mcg./ml, zinc 5 mg./ml.Nutrition Journal 2004, 3 http://www.nutritionj.com/content/3/1/6
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Table 2: Pre-/Post IV Treatment Data – 39 Patients Percent Predicted, Pre- and Post- infusion with % improvement
FVC (L) FEV 1 (L) PEF (L/S) FEF 25–75 (L/S) FEF 75–85 (L/S)
Sex Age % Predicted % Predicted % Predicted % Predicted % Predicted
Patient P r e P o s t% P r e P o s t% P r e P o s t% P r e P o s t% P r e P o s t%
A, L. M 55 36 72 100% 36 79 119% 64 92 44% 35 129 269% 32 112 250%
A, S. F 48 28 50 79% 30 48 60% 40 78 95% 30 40 33% 40 38 -5%
B, M. F 57 69 100 45% 48 81 69% 45 115 156% 24 39 63% 30 32 7%
B, R. M 46 73 93 27% 69 87 26% 95 106 12% 57 70 23% 66 67 2%
B, V. F 39 34 67 97% 34 72 112% 51 59 16% 38 96 153% 26 98 277%
B, V. F 70 38 54 42% 32 47 47% 32 53 66% 18 30 67% 25 34 36%
C, D. M 59 27 30 11% 14 17 21% 10 12 20% 10 10 0% 32 28 -13%
C, A. F 33 90 91 1% 80 98 23% 115 142 23% 60 108 80% 65 116 78%
C, K. F 35 45 62 38% 34 52 53% 32 56 75% 22 36 64% 32 41 28%
D, C. F 33 65 65 0% 49 56 14% 62 65 5% 31 41 32% 42 51 21%
D, B. M 49 65 80 23% 72 83 15% 68 88 29% 75 80 7% 146 147 1%
D, K. F 48 61 74 21% 56 70 25% 89 95 7% 39 60 54% 29 33 14%
F, L. M 58 26 29 12% 12 13 8% 7814% 7.4 8.1 9% 22 26 18%
G, W. M 74 48 67 40% 25 57 128% 16 88 450% 11 37 236% 38 63 66%
G, B. M 45 83 113 36% 83 101 22% 94 149 59% 81 70 -14% 89 60 -33%
G, G. F 42 83 93 12% 46 82 78% 24 59 146% 31 66 113% 55 79 44%
G, L. F 63 50 78 56% 36 60 67% 52 71 37% 17 29 71% 21 29 38%
J, E. F 63 47 85 81% 38 84 121% 43 64 49% 19 79 316% 20 55 175%
K, H. F 49 58 72 24% 59 72 22% 82 99 21% 53 62 17% 76 86 13%
M, A. F 46 85 97 14% 79 89 13% 61 86 41% 71 71 0% 73 68 -7%
M, W. M 85 74 77 4% 69 90 30% 46 82 78% 50 119 138% 148 458 209%
M, C. F 36 93 85 -9% 52 53 2% 30 46 53% 26 25 -4% 26 25.5 -2%
M, J. M 64 74 75 1% 49 57 16% 47 60 28% 25 37 48% 57 83 46%
O, M F 49 90 99 10% 98 114 16% 88 167 90% 114 168 47% 145 214 48%
P, O. F 47 54 72 33% 52 76 46% 85 84 -1% 46 82 78% 40 74 85%
R, B. F 69 21 23 10% 16 19 19% 13 17 31% 10 11 10% 21 22 5%
S, M. F 60 56 94 68% 45 88 96% 60 104 73% 26 66 154% 26 51 96%
S, J. M 54 98 166 69% 76 96 26% 77 70 -9% 34 39 15% 70 90 29%
S, S. M 40 73 85 16% 58 69 19% 68 85 25% 36 40 11% 43 38 -12%
S, D. F 64 40 56 40% 25 33 32% 18 21 17% 15 14 -7% 42 34 -19%
S, W. M 44 71 80 13% 52 65 25% 42 60 43% 31 40 29% 31 38 23%
T, P. F 45 41 59 44% 26 46 77% 22 73 232% 17 27 59% 26 32 23%
W, P. F 65 48 76 58% 17 31 82% 92 1 133% 91 1 22% 20 19 -3%
W, B. M 38 54 72 33% 42 58 38% 32 46 44% 25 37 48% 37 50 35%
W, R. M 40 77 77 0% 34 41 21% 27 33 22% 12 16 33% 21 24 14%
W, C. F 55 28 39 39% 20 28 40% 17 26 53% 12 16 33% 20 23 15%
W, G. F 70 101 108 7% 78 98 26% 34 82 141% 51 65 27% 49 62 27%
Z, A. F 43 62 75 21% 64 75 17% 107 87 -19% 68 88 29% 57 49 -14%
Average: 52 60 76 28% 48 65 38% 50 72 44% 35 54 54% 48 70 44%
Average Overall Improvement 45%
Results were measured as percentage improvement of the percentage predicted on the Knudsen scale
Table 3: Summary, Pre- and Post-IV Treatment Spirometry Results – 39 patients (Acute Asthma Protocol) Acute Asthma Pre- and 
Post-infusion Values Measured in Percent Predicted
Parameter Pre-IV Post-IV Ave. % Improved
FVC (L) 60 76 28%
FEV 1 (L) 48 65 38%
PEF (L/S) 50 72 44%
FEF 25–75 (L/S) 35 54 54%
FEF 75–85 (L/S) 48 70 44%
Total Average Improvement 45%
Results were measured as percentage improvement in the percentage predicted on the Knudsen scaleNutrition Journal 2004, 3 http://www.nutritionj.com/content/3/1/6
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fared considerably better than those who stopped therapy
within a month or less.
Patients experienced rapid clinical relief during – or at
some time after – most infusions, depending on their
degree of distress, and as the data demonstrates, pulmo-
nary function improved overall during the sequential
infusion study. It would also appear that the effectiveness
of this type of therapy might be cumulative, as patients
appeared to require treatment less often as time passed.
Drug usage was decreased in all patients, and discontin-
ued or reduced to intermittent use in over half of the
patients studied.
The primary reason mixed nutrients were employed in
this study is that prior to this study the author had
observed that the effect of a combination of nutrients was
consistently more beneficial than the infusion of IV mag-
nesium sulfate alone. Patients given magnesium (sulfate)
alone also seemed to develop a more rapidly increasing
tolerance for (or resistance to) magnesium, and
pulmonary function did not improve nearly as signifi-
cantly as were those of patients who were given the com-
plete protocols. Therefore, infusions of magnesium
sulfate alone, without other nutrients added, was not
employed in this study.
It has been demonstrated previously that intravenous
infusions with magnesium sulfate appear to be more
effective that nebulized albuterol alone [26], and it has
also been demonstrated that intravenous magnesium may
be successful when all other more "traditional" interven-
tions, including corticosteroids, have failed [28]. Consid-
Table 4: Trend Data – 13 Patients
% Predicted % Predicted % Predicted % Predicted % Predicted





Pre Post % Pre Post % Pre Post % Pre Post % Pre Post %
B, M. F 57 9.5 11 73 97 33% 56 78 39% 89 109 22% 26 41 58% 29 40 38%
B, C M 31 2.3 8 34 97 185% 39 69 77% 30 53 77% 17 45 165% 13 52 300%
D, K F 16 5.3 11 119 143 20% 94 96 2% 95 134 41% 54 37 -31% Not done
G, W. M 74 3.5 4 48 67 40% 25 57 128% 16 93 481% 11 34 209% 38 54 42%
G, L. F 63 3 4 50 82 64% 36 65 81% 51 56 10% 17 35 106% 21 36 71%
H, K. F 55 5.3 11 61 105 72% 41 97 137% 56 120 114% 18 38 111% 20 43 115%
L, L. F 53 0.3 2 40 87 118% 42 69 64% 50 47 -6% 38 47 24% 62 49 -21%
O, M. F 48 19 4 72 90 25% 63 98 56% 60 88 47% 42 114 171% 42 145 245%
P, R. M 77 1 6 65 88 35% 66 89 35% 73 92 26% 57 80 40% 165 171 4%
R, B. F 49 0.2 3 59 72 22% 59 71 20% 44 80 82% 61 70 15% 67 49 -27%
S, L. F 64 10 9 61 86 41% 41 64 56% 73 113 55% 16 24 50% 27 22 -19%
S, W. M 44 16 13 45 98 118% 35 77 120% 34 98 188% 21 45 114% 31 46 48%
W, G. F 70 0.2 2 65 74 14% 38 64 68% 16 47 194% 20 42 110% 21 64 205%
Average 54 5.82 6.77 61 91 50% 49 76 57% 53 87 64% 31 50 64% 45 64 44%
Ave. # IVs per patient per month 1.16
Average Overall Improvement 57%
Results were measured as percentage improvement in the percentage predicted on the Knudsen scale
Table 5: Trends in Patients with Chronic Asthma – 13 patients Trend Values Measured in Percent Predicted
Parameter Beginning of Therapy Conclusion of Therapy Ave. % Improved
FVC (L) 61 91 50%
FEV 1 (L) 49 76 57%
PEF (L/S) 53 87 64%
FEF 25–75 (L/S) 31 50 64%
FEF 75–85 (L/S) 45 64 44%
Total Average Improvement 57%
Trend values were obtained by subtracting the results of the first spirometry testing in the series from the results of the last (most current) in the 
series. Results were measured as percentage improvement in the percentage predicted on the Knudsen scale.Nutrition Journal 2004, 3 http://www.nutritionj.com/content/3/1/6
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ering this, the results of this study came as no surprise to
the author.
There are numerous metabolic and biochemical explana-
tions as to why each of the specific nutrients added might
indeed provide more benefit for asthmatics than magne-
sium sulfate alone. For example, Vitamin C is known to
have a general antihistaminic effect [39], it decreases
bronchial responsiveness overall [40] and bronchial
responsiveness to histamine in patients with allergic rhin-
itis [41]. Vitamin C is also a potent free radical scavenger,
and free radicals are known to play a role in the cause of
airway obstruction attendant with asthma [42].
Trace minerals also mitigate the inflammatory response
[43], perhaps because they play a major role in the anti-
oxidation of free radicals [44]. Further, manganese has
been found deficient in bronchial biopsies of asthmatic
patients, indication manganese replenishment could aid
in the treatment of asthma. [45].
Lastly, zinc is an essential trace mineral for most immune
mechanisms in the body to function, including lym-
phocyte (T-cell) function [46].
This reasoning could partly explain why the patients in
this study who received longer-term therapy with infu-
sions fared best. Molybdenum, as Wright's study demon-
strated [36], may be a significant part of the long-term
Table 6: Short-term Trend Data (infusions for one month or less) 4 Patients
% Predicted % Predicted % Predicted % Predicted % Predicted
FVC (L) FEV 1 (L) PEF (L/S) FEF 25–75 (L/S) FEF 75–85 (L/S)
Patient Sex Age Mos
.
# IVs per 
pt.
Pre Post % Pre Post % Pre Post % Pre Post % Pre Post %
L, L. F 53 0.3 2 40 87 118% 42 69 64% 50 47 -6% 38 47 24% 62 49 -21%
P, R. M 77 1 6 65 88 35% 66 89 35% 73 92 26% 57 80 40% 165 171 4%
R, B. F 49 0.2 3 59 72 22% 59 71 20% 44 80 82% 61 70 15% 67 49 -27%
W, G. F 70 0.2 2 65 74 14% 38 64 68% 16 47 194% 20 42 110% 21 64 205%
Average 62 0.43 3.25 57 80 40% 51 73 43% 46 67 45% 44 60 36% 79 83 6%
Ave. # IVs per patient 3.25
Average Overall Improvement 34% Short Term
Results were measured as percentage improvement in the percentage predicted on the Knudsen scale
Table 7: Long-term Trend Data (infusion for over a month) 9 Patients
% Predicted % Predicted % Predicted % Predicted % Predicted
Patient FVC (L) FEV 1 (L) PEF (L/S) FEF 25–75 (L/S) FEF 75–85 (L/S)
Sex Age Mos. # IVs 
Per pt.
Pre Post % Pre Post % Pre Post % Pre Post % Pre Post %
B, M. F 57 9.5 11 73 97 33% 56 78 39% 89 109 22% 26 41 58% 29 40 38%
B, C M 31 2.3 8 34 97 185% 39 69 77% 30 53 77% 17 45 165% 13 52 300%
D, K F 16 5.3 11 119 143 20% 94 96 2% 95 134 41% 54 37 -31% Not 
done
G, W. M 74 3.5 4 48 67 40% 25 57 128% 16 93 481% 11 34 209% 38 54 42%
G, L. F 63 3 4 50 82 64% 36 65 81% 51 56 10% 17 35 106% 21 36 71%
H, K. F 55 5.3 11 61 105 72% 41 97 137% 56 120 114% 18 38 111% 20 43 115%
O, M. F 48 19 4 72 90 25% 63 98 56% 60 88 47% 42 114 171% 42 145 245%
S, L. F 64 10 9 61 86 41% 41 64 56% 73 113 55% 16 24 50% 27 22 -19%
S, W. M 44 16 13 45 98 118% 35 77 120% 34 98 188% 21 45 114% 31 46 48%
Average 53 12.58 9.25 60 95 59% 45 84 87% 56 105 88% 24 55 128% 30 64 113%
Ave. # IVs per patient per month 0.7
4
Average Overall Improvement 95
%
Long Term
Results were measured as percentage improvement in the percentage predicted on the Knudsen scaleNutrition Journal 2004, 3 http://www.nutritionj.com/content/3/1/6
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benefit. Indeed, those patients who received an average of
less than one infusion monthly for over a year fared
almost three times as well as those who received infusions
for a month or less.
Over the period of this study, the author observed that 6
of 44 asthmatic patients appeared to fail with this partic-
ular type of infusion therapy. These 6 patients, however,
were judged as failures prior to any patient having
received three IV treatments. Since this study was under-
taken, the author has found that it sometimes takes 3 to 5
infusions for patients to observe a substantial clinical ben-
efit. Therefore, actual failure may be in question.
Shortly after this study was first begun, it became clear
that patients who received weekly or more frequent ther-
apy with these parenteral nutrients for a period of 1 1/2 to
3 months improved more rapidly and distinctly than
patients who received only occasional infusions. It also
became evident that this group of patients was able to
extend the interval between treatments to 8–14 days and
then longer. Several patients were able to extend their
intervals out as far as 4–6 months with little apparent loss
of efficacy.
This led the author to reach the preliminary conclusion
that there may be some type of "loading" period, or dose
accumulation, of one or more of these nutrients
employed here. Dr. Wright, working with intravenous
molybdenum for asthma, discovered this same phenome-
non [36].
It was also often observed that patients with acute asthma
sometimes did not improve immediately, or even
appeared to worsen immediately after an infusion. This is
very likely secondary to the acute bronchodilitation
resulting from this treatment, with resultant mucous pro-
duction (release) and coughing. Studies have shown that
optimal pulmonary function is likely to occur considera-
bly later than 10 minutes after an infusion of magnesium,
even out to perhaps 80–110 minutes [10]. The author's
experience supports this observation and it is likely that
the post-infusion measurements in this study were usually
taken before the maximum benefit occurred.
As a more important note, the author observed that the
Infusion protocol, when given as the initial treatment,
whether for a patient with acute or chronic asthma, could
cause considerable worsening of symptoms several hours
after the infusion. Early in the study, three patients who
were given the Infusion as their first treatment experi-
enced increased respiratory distress later in the day, two of
which required emergency treatment. The author postu-
lates that the infusion administration of either the molyb-
denum or the trace minerals (containing molybdenum)
prior to "priming" a patient with at least one IV that does
not contain minerals can cause an adverse reaction.
Although the mechanism of this reaction is not yet clear,
the author speculates this response may be secondary to
an acute sulfite detoxification response to molybdenum.
Considering this, the author advises that neither trace
minerals nor molybdenum be included in any rapidly
infused IV or in any IV to be administered for acute
asthma.
The author would conclude that parenteral infusion ther-
apy with the nutrients used in this study might have con-
siderable benefit. Infusions of these particular parental
nutrients very often made the difference for patients who
otherwise were responding poorly to other modalities of
treatment.
As a result of this study, the author is of the opinion that
this type of therapy adds a dimension to the treatment of
chronic asthma not attainable with conventional therapy
using bronchodilators and corticosteroids, especially in
the acute situation.
In a time when multiple factors appear to be coalescing to
increase both the incidence and morbidity of asthma
around the world, it would seem that any therapy that
adds a measure of exclusion from these statistics should
be considered whenever possible.
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